Consequently, we speculate that in the high PRTFDC1 expression group, tumor cells may be more reliant on the purine nucleotide salvage pathway to promote proliferation, rather than on the signaling pathways activated by KIT, NRAS, or KRAS mutations. The gene discussed is KRAS; the disease is neoplasm.